Literature DB >> 19125880

Verapamil for cluster headache. Clinical pharmacology and possible mode of action.

Peer Tfelt-Hansen1, Jacob Tfelt-Hansen.   

Abstract

Verapamil is used mainly in cardiovascular diseases. High-dose verapamil (360-720 mg) is, however, currently the mainstay in the prophylactic treatment of cluster headache. The oral pharmacokinetics are variable. The pharmacodynamic effect of verapamil, the effect on blood pressure, also varies considerably among subjects. The dose of verapamil used for cluster headache is approximately double the dose used in cardiovascular disease, most likely because verapamil is a substrate for the efflux transporter P-glycoprotein in the blood-brain barrier. The access of verapamil to the central nervous system is therefore limited. The clinical use of verapamil in cluster headache is reviewed and several relevant drug interactions are mentioned. Finally, its possible mode of action in cluster headache is discussed. The effect of verapamil in cluster headache most likely takes place in the hypothalamus.Verapamil is an L-type calcium channel blocker but it is also a blocker of other calcium channels (T-, P-, and possibly N- and Q-type Ca(2+) channels) and the human ether-a-go-go-related gene potassium channel. With so many different actions of verapamil, it is impossible at the present time to single out a certain mode of action of the drug in cluster headache.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125880     DOI: 10.1111/j.1526-4610.2008.01298.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  13 in total

Review 1.  Management of headache in the elderly.

Authors:  Matthew S Robbins; Richard B Lipton
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.

Authors:  Anniina Koski; Mari Raki; Petri Nokisalmi; Ilkka Liikanen; Lotta Kangasniemi; Timo Joensuu; Anna Kanerva; Sari Pesonen; Ramon Alemany; Akseli Hemminki
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

3.  Can verapamil be effective in controlling vertigo and headache attacks in vestibular migraine accompanied with Meniere's disease? A preliminary study.

Authors:  Isa Kaya; Sevinc Eraslan; Ceyda Tarhan; Cem Bilgen; Tayfun Kirazli; Figen Gokcay; Hale Karapolat; Nese Celebisoy
Journal:  J Neurol       Date:  2019-04-15       Impact factor: 4.849

4.  Management of cluster headache.

Authors:  Peer C Tfelt-Hansen; Rigmor H Jensen
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 5.  Evidence-based treatments for cluster headache.

Authors:  Rubesh Gooriah; Alina Buture; Fayyaz Ahmed
Journal:  Ther Clin Risk Manag       Date:  2015-11-09       Impact factor: 2.423

6.  Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.

Authors:  Kristin N Adams; John D Szumowski; Lalita Ramakrishnan
Journal:  J Infect Dis       Date:  2014-02-14       Impact factor: 5.226

7.  Dorsolateral medullary ischemic infarction causing autonomic dysfunction and headache: a case report.

Authors:  Riccardo Altavilla; Doriana Landi; Claudia Altamura; Gennaro Bussone; Paola Maggio; Marzia Corbetto; Federica Scrascia; Fabrizio Vernieri
Journal:  J Headache Pain       Date:  2012-02-29       Impact factor: 7.277

8.  Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day).

Authors:  M Lanteri-Minet; F Silhol; V Piano; A Donnet
Journal:  J Headache Pain       Date:  2011-01-22       Impact factor: 7.277

9.  Detection, isolation and characterization of principal synthetic route indicative impurities in verapamil hydrochloride.

Authors:  Viswanathan Srinivasan; Hariharan Sivaramakrishnan; Balakrishnan Karthikeyan
Journal:  Sci Pharm       Date:  2011-05-08

10.  The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1.

Authors:  Lasse Saaby; Peer Tfelt-Hansen; Birger Brodin
Journal:  Pharmacol Res Perspect       Date:  2015-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.